InvestorsObserver
×
News Home

Is Novartis AG (NVS) a Stock to Watch After Losing -2.49% This Week?

Tuesday, September 21, 2021 01:31 PM | InvestorsObserver Analysts

Mentioned in this article

Is Novartis AG (NVS) a Stock to Watch After Losing -2.49% This Week?

Novartis AG (NVS) stock is lower by 2.49% over the past week and gets a Bearish rating from InvestorsObserver Sentiment Indicator.

Sentiment Score - ,bearish
Novartis AG has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on NVS!

What is Stock Sentiment?

In investing, sentiment generally means whether or not a given security is in favor with investors. It is typically a pretty short-term metric that relies entirely on technical analysis. That means it doesn’t incorporate anything to do with the health or profitability of the underlying company. Price action is generally the best indicator of sentiment. For a stock to go up, investors must feel good about it. Similarly, a stock that is in a downtrend must be out of favor. InvestorsObserver’s Sentiment Indicator considers price action and recent trends in volume. Increasing volumes often mean that a trend is strengthening, while decreasing volumes can signal that a reversal could come soon. The options market is another place to get signals about sentiment. Since options allow investors to place bets on the price of a stock, we consider the ratio of calls and puts for stocks where options are available.

What's Happening With NVS Stock Today?

Novartis AG (NVS) stock is trading at $83.16 as of 1:28 PM on Tuesday, Sep 21, a rise of $0.35, or 0.42% from the previous closing price of $82.81. Volume today is less active than usual. So far 1,185,005 shares have traded compared to average volume of 1,931,599 shares. The stock has traded between $83.14 and $83.92 so far today. To see InvestorsObserver's Sentiment Score for Novartis AG click here.

More About Novartis AG

Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The firm sells its products globally, with the United States representing close to one third of total revenue. Click Here to get the full Stock Report for Novartis AG stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App